Bull, Bear & Beyond – IRLAB Therapeutics: executive interview

IRLAB Therapeutics (OMX: IRLAB-A) is a Sweden-based biopharma company focused on the development of novel treatments for neurodegenerative diseases, with a particular focus on Parkinson’s disease (PD). The company has a highly active pipeline, with assets spanning all stages of clinical development, from preclinical programmes through to its lead asset, mesdopetam, which is Phase III-ready.

In this podcast we speak to Kristina Torfgård, IRLAB’s new CEO as of August 2024, and learn more about her wealth of experience in drug development, what drew her to IRLAB and her strategic priorities as the company approaches key upcoming milestones.

Listen on your preferred podcast player below:

Spotify
YouTube
Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets. These discussions offer unique insight into how leaders navigate challenges, drive growth, and deliver long-term value for stakeholders.